Clinical supply chains have a wastage problem, and the industry knows it. Sponsors have historically padded site inventory with overages to guard against the unknowns of enrolment, dropout, and demand variability, a buffer that quietly inflates the cost of every trial it protects. The gap between what a study actually needs and what it is forced to stock is not a rounding error; on a mid-sized global study, trimming overage from 200 percent to 50 percent can mean the difference of well over a million dollars in unused, wasted IMP.
That gap exists because most supply management solutions work by answering yesterday’s question: has inventory crossed a fixed line? In RTSM parlance it is termed as resupply thresholds or simply Min / Max.
As early as 1997, S-Clinica was a pioneer that broke away from min/max and threshold-based methods approaches to clinical supply management. Over the years, we have continuously evolved our algorithm to redefine how supply decisions are made — shifting from backward-looking rules to forward-looking intelligence.
Given everything happening at a site right now, what is actually likely to happen next, and how confident can we be in that answer? We called it our anticipatory management engine.
An Industry Moving Toward Probability
This is not a fringe idea. Probability-based supply management and forecasting, built on Monte Carlo simulations and Bayesian inference, has been steadily gaining ground across clinical development, not just in supply, but in trial design itself. Monte Carlo methods generate thousands of plausible trial trajectories from a set of known inputs, producing a full range of likely outcomes rather than a single fragile estimate. Bayesian inference goes a step further: it takes that estimate and continuously revises it as real data arrives, blending prior knowledge with what is actually being observed.
Regulators have taken notice. In January 2026, the FDA issued a draft guidance on the use of Bayesian methodology in clinical trials of drugs and biological products, jointly from CDER and CBER, formalizing what had been years of accumulating regulatory experience with the approach. The guidance describes Bayesian analysis as a process where data collected during a study is combined with a prior distribution to form a posterior, an updated view of what is most likely true, and explicitly frames this as a continuous learning process rather than a single-point calculation. Industry commentary has called it a genuine turning point for Bayesian methods in regulated drug development.
We see this as validation of a direction – academic literature on clinical supply forecasting has explored Bayesian re-evaluation of supply strategy since at least the late 2000s, and the broader shift toward simulation-based, probability-driven planning has only accelerated since.
S-Clinica built its own engine around these same principles well ahead of that curve, and purpose-built it for a domain most generic forecasting tools were never designed to handle: the regulatory, ethical, and operational constraints unique to clinical trials.
Our Engine: Predictive Probability, Adjusted in Real Time
The core of our system runs on three key pillars driving this industry-wide shift, probability-based adjusted to real time algorithms, Monte Carlo simulations and Bayesian inference, but with one critical difference in how they are applied. Where many forecasting tools generate a probability model once and revisit it on a fixed schedule, our engine is built to be self-correcting adjusted in real time: every collected data point from a site, actual enrolment pace, actual dispensing behaviour, an unexpected dropout, feeds directly back into the model the moment it occurs, and the algorithm self-corrects its recommendation accordingly.
In practice, this means the system is never working from a stale snapshot. A site that suddenly enrols faster than projected, or a region showing early signs of higher-than-expected dropout, shifts the underlying probability distribution immediately, and the supply plan adjusts with it, before a shortfall or a surplus can materialize.
This is the difference between a system that reports on inventory and one that actively manages risk as it evolves.
This self-correcting loop is only possible because we built the forecasting engine and our RTSM platform on the same backend. Enrolment, dispensing, and inventory data do not pass through a delayed API integration before reaching the model; they inform it instantly. For sponsors that translates into meaningfully less safety stock without a corresponding rise in stock out risk precisely the trade off a static system can never fully solve, since it always has to buffer against uncertainty it cannot see coming.
RTSM & Supply Management: Power of single setup and single database
A single-setup, single-database RTSM and Supply Management architecture transforms the way clinical trials operate by eliminating the fragmentation that traditionally slows teams down. When randomization, drug assignment, inventory forecasting, depot management, and site-level supply decisions all run from one unified environment, every stakeholder—from clinical operations to supply chain—works from the same source of truth. This dramatically reduces reconciliation work, prevents data mismatches, and enables real-time visibility across the entire trial. Instead of stitching together multiple systems, sponsors gain a streamlined workflow where protocol changes, country additions, and mid-study updates propagate instantly and consistently. The result is tighter control, fewer errors, faster study start up, and a more resilient supply chain that can adapt dynamically to patient enrollment and site behaviour. In short, a single setup and single database unlock the true power of RTSM: operational simplicity, data integrity, and end-to-end efficiency.
Why This Matters Beyond the Balance Sheet
The financial case is real and well documented across the industry: risk-based, simulation-driven approaches to comparator sourcing and overage reduction have been shown to cut total drug waste by as much as 20 to 60 percent in published case studies, with individual programs reporting tens of millions of dollars in savings from bringing overage down to more disciplined levels. But the stakes go beyond cost. As personalized and time-sensitive therapies, including cell, gene, and radiopharmaceutical products, become a larger share of the development pipeline, the margin for a reactive, one-size-fits-all supply model shrinks to almost nothing. When a product’s usable window is measured in hours, a forecasting engine that updates on a schedule is no longer good enough. It has to adjust as fast as the situation on the ground changes.
Built, Not Bought
With vendors rushing to plug in AI it’s worth distinguishing between companies using off-the-shelf AI agents and those who actually write the science.
Long before AI became mainstream, we recognized that traditional clinical supply chains were broken. Reactive, rigid Min/Max thresholds were driving massive drug wastage, overages, and stock out risk. So we solved it — becoming the first to adapt real AI into a smart clinical logistics algorithm. And we did it on our own terms:
Built by our own clinical experts, biostatisticians, and mathematicians.
Powered by the S-Clinica Anticipatory Management Engine — a 100% proprietary, custom-built AI model designed specifically for the unique, highly regulated realities of clinical trials.
We didn’t wait for the AI revolution — we started adapting it to clinical supply chains over two decades ago, building our own engine from scratch to keep global trials running flawlessly across 119+ countries.
Ready to experience true clinical supply chain optimization?
Let’s connect.